Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer

Brachytherapy

Volumn 11, Issue 6, 2012, Pages 441-445

  Shah, Chirag ^a   Lanni, Thomas B ^a   Ghilezan, Mihai I ^a   Gustafson, Gary S ^a   Marvin, Kimberly S ^a   Ye, Hong ^a   Vicini, Frank A ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Brachytherapy; Cost effectiveness; IMRT; Prostate cancer

Indexed keywords

PALLADIUM; RADIOACTIVE SEED;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; REIMBURSEMENT; TREATMENT FAILURE;

BRACHYTHERAPY; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MICHIGAN; PREVALENCE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84868098159     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.04.002     Document Type: Article

References (20)

1. Cancer facts and figures 2010. American Cancer Society. Available at: Accessed November 5, 2011. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010.
2. Horner M.J., Krapcho M., Neyman N., et al. SEER cancer statistics review, 1975-2006 2009, National Cancer Institute, Bethesda, MD.
3. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy >= 72 Gy, permanent seed implantantion, or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:25-33.
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
5. Mariotto A.B., Yabroff K.R., Shao Y., et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103:117-128.
6. Hummel S., Simpson E.L., Hemingway P., et al. Intensity-modulated radiotherapy for the treatment of prostate cancer: A systematic review and economic evaluation. Health Technol Assess 2010, 14:1-108.
7. Martinez A.A., Pataki I., Edmundson G., et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys 2001, 49:61-69.
8. Fowler J.F., Ritter M.A., Chappell R.J., et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 56:1093-1104.
9. Yan D., Lockman D., Brabbins D., et al. An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48:289-302.
10. Mohammed N., Kestin L., Ghilezan M., et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:204-212.
11. Snyder C.F., Frick K.D., Blackford A.L., et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?. Cancer 2010, 116:5391-5399.
12. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
13. Tengs T.O., Adams M.E., Pliskin J.S., et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995, 15:369-390.
14. Hayes J, McMahon P, Pearson SD, Institute For Clinical and Economic Review; Final Appraisal Document. Brachytherapy and proton beam therapy for treatment of clinically-localized, low risk prostate cancer. Institute for Clinical and Economic Review. Available at: Accessed 11/5/2011. http://www.icerreview.org/index.php?option_com_content&task_view&id_18&Itemid_39.
15. Warren J.L., Yabroff K.R., Meekins A., et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008, 100:888-897.
16. Lottan Y., Cadeddu J.A., Gettman M.T. The new economics of radical prostatectomy: Cost comparison of open, laparascopic, and robot assisted techniques. J Urol 2004, 172:1431-1435.
17. LottanY Economics of robotics in urology. Curr Opin Urol 2010, 20:92-97.
18. Burkhardt J.H., Litwin M.S., Rose C.M., et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 2002, 20:2869-2875.
19. Buron C., Le Vu B., Cosset J.M., et al. Brachytherapy versus prostatectomy in localized prostate cancer: Results of a French multicenter prospective medico-economic study. Int J Radiat Oncol Biol Phys 2007, 67:812-822.
20. Porter M.E. What is the value of health care?. N Engl J Med 2012, 363:2477-2481.